Thursday, Jan 29 / 2026
Virtual Meeting
  • Thursday, January 29, 2026
  • 10:00 AM - 10:45 AM PST
  • Virtual Only
  • → Join Online
  • Access will be granted upon approval
Download for Outlook/Apple Calendar Add to Google Calendar

DD Call with Leaf4Life

Leaf4Life
KizaVie. Transforming Hypoxia from an Unsolved Challenge into a Therapeutic Opportunity. Hypoxia, a leading cause of 30 million deaths annually, drives mortality across cancer, ARDS, shock and trauma, cardiovascular and ischemic stroke and other conditions, yet no therapy directly corrects it. KizaVie is the first drug (medicine) to reverse hypoxia in ARDS patients in ICU and achieved 92% survival rates at 90-day time point compared to 40% with SOC.

Presenting companies:

Leaf4Life
Leaf4Life

KizaVie™ (LEAF-4L6715) is a late-stage, first-in-class therapeutic platform designed to restore oxygen diffusion at the microvascular level—addressing a fundamental physiological limitation that drives mortality, treatment resistance, and healthcare burden across critical care, oncology, trauma, and chronic disease. Unlike conventional therapies that increase oxygen supply, KizaVie™ enables oxygen delivery at the tissue level, directly targeting a core biological failure not addressed by current standards of care.